Remove Adverse Reactions Remove Mayo Clinic Remove Pharmaceutical Companies
article thumbnail

Innovation in immuno-oncology: Leading companies in oncolytic viral proteins

Pharmaceutical Technology

A major strategy for OV development is genetic manipulation to weaken virus pathogenicity, enhance target selectivity, reduce adverse reactions, and/or insert exogenous therapeutic genes into the virus genome. OVs can be attenuated natural viruses or recombinant viruses.